Prevention and treatment of corticosteroid-induced osteoporosis

Yonsei Medical Journal

Volumn 46, Issue 4, 2005, Pages 456-463

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

Author keywords

Bisphosphonate; Bone mineral density (BMD); Corticosteroid; Meta analysis; Osteoporosis; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; FARNOQUINONE; METHYLPREDNISOLONE; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RISEDRONIC ACID;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; CALCIUM ABSORPTION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HOMEOSTASIS; HUMAN; INCIDENCE; LUMBAR SPINE; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

EID: 24644471438     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2005.46.4.456     Document Type: Review

References (35)

1. Hodgson SF. Corticosteroid-induced osteoporosis. Endocrinol Metab Clin North Am 1990;19:95-111.
2. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind. J Bone Miner Res 2000; 15:1001-5.
3. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9.
4. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
5. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
6. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
7. Dennison E. Epidemiology of glucocorticoid-induced osteoporosis. Osteoporos Int 1999;9:S16.
8. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton III LJ, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893-9.
9. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
10. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.
11. Malolagas SC, Weinstein RS, Bellido T, Bodenner DL, Jilka RL, Parfitt AM. Activators of non-genomic estrogen-like signaling (ANGELS): a novel class of small molecules with bone anabolic properties. J Bone Miner Res 1999;14:S180.
12. Weinstein RS, Bellido T, Chambers TM, Crawford JA, Swain FL, Han L, et al. Like estrogen, androgen exerts potent and direct anti-apoptotic effects on osteoblasts and osteocytes in vivo and in vitro. J Bone Miner Res 1999;14:S451.
13. Plotkin L, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblasts apoptosis by bisphosponates and calcitonin. J Clin Invests 1999;104:1363-74.
14. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with PTH. J Clin Invest 1999;104:439-46.
15. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug used for the management of corticosteroid-induced osteoporosis: a mata-regression. J Bone Miner Res 2002;17:1512-26.
16. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;2:CD000952.
17. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004;15:301-10.
18. Cranney A, Wekch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;2:CD001983.
19. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000;2: CD001347.
20. Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000;27:2424-31.
21. Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fuji T, et al. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year follow-up. J Rheumatol 2003;30:2673-9.
22. Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate, prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 2004;31:163-6.
23. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
24. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000;11:331-7.
25. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999;42: 2309-18.
26. Reid DM, Hughes RA, Laan R, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000;15:1006-13.
27. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treat with and without steroids. Arthritis Rheum 1994;37:1499-505.
28. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud C. Bone mass continue to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000; 15:944-51.
29. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047.
30. 2 on osteoporosis. Curr Pharm Design 2004;10:2557-76.
31. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988;3:113-5.
32. Tanaka I, Ohshima K. Prevention of vertebral fractures with therapeutic agents in corticosteroid-induced osteoporosis. Osteoporosis Japan 2002;10:244-7 (in Japanese).
33. Tanaka I, Ohshima K. Effects of menatetrenone, a vitamin K analogue, on prevention of vertebral fracture in corticosteroid-induced osteoporosis. J Bone Miner Res 2001;16 Suppl:S531.
34. Tanaka I, Ohshima K. A longitudinal study of diagnosis and treatment for corticosteroid-induced osteoporosis. Osteoporosis Japan 2003;11:11-4 (in Japanese).
35. 2 and bisphosphonate in postmenopausal women with osteoporosis. Yonsei Med J 2003; 44:508-16.